We reported the concentration of serum sHLA-G protein as well as mRNA expression levels before and after receiving therapy to establish sHLA-G as diagnostic and prognostic protein marker for HNSCC patients. This evidence concerns the gene HLA-G and head and neck squamous cell carcinoma.